Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.

by Geraint Davies, Martin Boeree, Dave Hermann, Michael Hoelscher
Published 2019-07-01

Otomastoiditis Caused by Mycobacterium abscessus, the Netherlands

by Jakko van Ingen, Frank Looijmans, Piet Mirck, Richard Dekhuijzen, Martin Boeree, Dick van Soolingen
Published 2010-01-01

The accuracy of an electronic nose to diagnose tuberculosis in patients referred to an expert centre.

by Rosarito Coronel Teixeira, Luis Gómez, Eva González, Nilda Jiménez de Romero, Felipe González, Sarita Aguirre, Martin Boeree, Robin Janssen, Cecile Magis-Escurra
Published 2023-01-01

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

by Charlotte Seijger, Wouter Hoefsloot, Inge Bergsma-de Guchteneire, Lindsey Te Brake, Jakko van Ingen, Saskia Kuipers, Reinout van Crevel, Rob Aarnoutse, Martin Boeree, Cecile Magis-Escurra
Published 2019-01-01

Immune defects in patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis

by Milou M.F. Schuurbiers, Mariolina Bruno, Sanne M.H. Zweijpfenning, Cecile Magis-Escurra, Martin Boeree, Mihai G. Netea, Jakko van Ingen, Frank van de Veerdonk, Wouter Hoefsloot
Published 2020-11-01

Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated...

by Stellah G. Mpagama, Happiness C. Mvungi, Peter M. Mbelele, Hadija H. Semvua, Alphonce A. Liyoyo, Kristen Petros de Guex, Derek Sloan, Gibson S. Kibiki, Martin Boeree, Patrick P. J. Phillips, Scott K. Heysell
Published 2023-04-01